Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). A case report
Valdenassi L, Rossi E, Corsetti MT, et al. European Review for Medical and Pharmacological Sciences, 2022.
- Study type
- Case report
- People studied
- 1 person
- Population
- Older adult with Sjögren syndrome
- Published
- 2022, European Review for Medical and Pharmacological Sciences
- Identifiers
- PMID 36066166, DOI 10.26355/eurrev_202208_29530
What the authors reported
A single older patient with Sjögren syndrome reported reduced pain and fatigue after a course of oxygen-ozone major autohemotherapy.
What limits this result
One patient, no control group, and no blinding; cannot separate any ozone effect from the natural course of the disease or other concurrent care.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Autoimmune Conditions: Rheumatoid Arthritis, MS, Lupus and the Evidence
What the ACR rheumatoid arthritis guideline and small ozone autohemotherapy studies actually show about EBO2 (also called EBOO) for autoimmune disease.